IMSPEX_DIAGNOSTICS_LIMITE - Accounts


Company Registration No. 07533570 (England and Wales)
IMSPEX DIAGNOSTICS LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2018
PAGES FOR FILING WITH REGISTRAR
IMSPEX DIAGNOSTICS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 11
IMSPEX DIAGNOSTICS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2018
31 December 2018
- 1 -
2018
2017
Notes
£
£
£
£
Fixed assets
Intangible assets
5
2,274,002
1,807,252
Tangible assets
6
54,278
140,685
Investments
7
8,560
8,560
2,336,840
1,956,497
Current assets
Stocks
1,290
167,671
Debtors
9
243,904
312,191
Cash at bank and in hand
373,708
586,356
618,902
1,066,218
Creditors: amounts falling due within one year
10
(666,390)
(1,144,864)
Net current liabilities
(47,488)
(78,646)
Total assets less current liabilities
2,289,352
1,877,851
Provisions for liabilities
(249,762)
(182,292)
Net assets
2,039,590
1,695,559
Capital and reserves
Called up share capital
11
292,951
292,951
Share premium account
1,586,060
1,586,060
Profit and loss reserves
160,579
(183,452)
Total equity
2,039,590
1,695,559

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and Financial Reporting Standard 102 section 1A for small companies.

The financial statements were approved by the board of directors and authorised for issue on 15 February 2019 and are signed on its behalf by:
Mr S D Dominguez Vivero
Director
Company Registration No. 07533570
IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2018
- 2 -
1
Accounting policies
Company information

Imspex Diagnostics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Ty Menter, Venture House, Navigation Park, ABERCYNON, Rhondda Cynon Taff, UK, CF45 4SN.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Turnover

The turnover shown in the profit and loss account represents amounts invoiced during the period, exclusive of Value Added Tax.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents
straight line over 20 years
Development Costs
straight line over 10 years
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies (Continued)
- 3 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
20% to 33% on a straight line basis
Fixtures, fittings & equipment
33% on a straight line basis
Computer equipment
33% on a straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies (Continued)
- 4 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies (Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to the profit and loss account so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies (Continued)
- 6 -
1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

1.17

Operating lease agreements

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight line basis over the period of the lease.

1.18

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

 

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

 

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

2
Change in accounting estimate

In this period, there has been a change in the accounting estimate of intangible assets development costs. The estimated useful life has been extended from 5 years to 10 years from this period. The affect of this change is to decrease the amortisation charge in the year ended 31 December 2018 from £429,160 to £160,274. The Directors believe this period of useful life to be more appropriate.

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 7 -
3
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Depreciation

Management reviews the useful lives of depreciable assets at each reporting date based on the expected utilitisation of the assets of the company. The carrying amounts are analysed in note 10. Actual results, however, may vary due to technical obsolescence.

Prepayments

Management recognises a prepayment asset, which have been invoiced at the year end but the cost may partially or in total relate to post period end. This is based on purchase invoices or goods invoiced not yet received.

Accruals

Management recognises a provision for liabilities, which have not been invoiced at the year end but which are likely to crystallise post period end. This is based on purchase orders.

Deferred income

The income relating to grant income is deferred and released over the period of the grant to which it relates.

4
Employees

The average monthly number of persons (including directors) employed by the company during the year was 6 (2017 - 6).

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 8 -
5
Intangible fixed assets
Patents
Development Costs
Total
£
£
£
Cost
At 1 January 2018
204,516
2,145,800
2,350,316
Additions - internally developed
-
657,693
657,693
At 31 December 2018
204,516
2,803,493
3,008,009
Amortisation and impairment
At 1 January 2018
-
543,065
543,065
Amortisation charged for the year
30,668
160,274
190,942
At 31 December 2018
30,668
703,339
734,007
Carrying amount
At 31 December 2018
173,848
2,100,154
2,274,002
At 31 December 2017
204,516
1,602,736
1,807,252
6
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2018 and 31 December 2018
238,706
Depreciation and impairment
At 1 January 2018
98,021
Depreciation charged in the year
86,407
At 31 December 2018
184,428
Carrying amount
At 31 December 2018
54,278
At 31 December 2017
140,685
7
Fixed asset investments
2018
2017
£
£
Investments
8,560
8,560

 

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 9 -
8
Subsidiaries

Details of the company's subsidiaries at 31 December 2018 are as follows:

Name of undertaking
Registered
Nature of business
Class of
% Held
office
shares held
Direct
Indirect
Gesellschaft fur analytische Seneorsysteme mbH
Germany
Analytical Chemistry
Ordinary
90.00
9
Debtors
2018
2017
Amounts falling due within one year:
£
£
Trade debtors
-
62,974
Corporation tax recoverable
206,949
178,353
Other debtors
36,955
70,864
243,904
312,191
10
Creditors: amounts falling due within one year
2018
2017
£
£
Bank loans and overdrafts
683
455
Trade creditors
58,461
24,193
Amounts owed to group undertakings
100,035
203,089
Corporation tax
-
7,157
Other taxation and social security
6,130
12,217
Other creditors
501,081
897,753
666,390
1,144,864

 

11
Called up share capital
2018
2017
£
£
Ordinary share capital
Issued and not fully paid
29,295,177 Ordinary shares of 1p each
292,951
292,951
292,951
292,951
IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 10 -
12
Audit report information

As the income statement has been omitted from the filing copy of the financial statements the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

The senior statutory auditor was Ian Thomas BSc FCA DChA.
The auditor was MHA Broomfield Alexander.
13
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2018
2017
£
£
3,482
7,805
14
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Sale of goods
Purchase of goods
2018
2017
2018
2017
£
£
£
£
Entities with control, joint control or significant influence over the company
649,336
412,992
103,669
45,836

 

2018
2017
Amounts owed to related parties
£
£
Entities over which the entity has control, joint control or significant influence
100,034
203,089
Other related parties
-
62,202

 

IMSPEX DIAGNOSTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 11 -
15
Directors' transactions

Dividends totalling £0 (2017 - £0) were paid in the year in respect of shares held by the company's directors.

At the year end the company owed the following to Directors: Mr D Hampson £1,969 (2017: £4,631 debtor) with a repayment of £6,600 in the period, and Mr S Dominguez £62,842 (2017: £20,590 debtor) with payments to the company of £44,124 in the period.

 

Interest is being charged on Mr S Dominguez's loan balance at 4%.

16
Parent company

The controlling parent is Hanon Inc Group Ltd.

 

In the opinion of the Directors there is no ultimate controlling party,

2018-12-312018-01-01falseCCH SoftwareCCH Accounts Production 2018.300No description of principal activity15 February 2019This audit opinion is unqualifiedMr D J HampsonMr Santiago Dominguez ViveroMr T WortelmannMr Z Wang075335702018-01-012018-12-31075335702018-12-31075335702017-12-3107533570core:PatentsTrademarksLicencesConcessionsSimilar2018-12-3107533570core:DevelopmentCostsCapitalisedDevelopmentExpenditure2018-12-3107533570core:PatentsTrademarksLicencesConcessionsSimilar2017-12-3107533570core:DevelopmentCostsCapitalisedDevelopmentExpenditure2017-12-3107533570core:OtherPropertyPlantEquipment2018-12-3107533570core:OtherPropertyPlantEquipment2017-12-3107533570core:CurrentFinancialInstruments2018-12-3107533570core:CurrentFinancialInstruments2017-12-3107533570core:ShareCapital2018-12-3107533570core:ShareCapital2017-12-3107533570core:SharePremium2018-12-3107533570core:SharePremium2017-12-3107533570core:RetainedEarningsAccumulatedLosses2018-12-3107533570core:RetainedEarningsAccumulatedLosses2017-12-3107533570core:ShareCapitalOrdinaryShares2018-12-3107533570core:ShareCapitalOrdinaryShares2017-12-3107533570bus:Director42018-01-012018-12-3107533570core:PlantMachinery2018-01-012018-12-3107533570core:FurnitureFittings2018-01-012018-12-3107533570core:ComputerEquipment2018-01-012018-12-3107533570core:PatentsTrademarksLicencesConcessionsSimilar2017-12-3107533570core:DevelopmentCostsCapitalisedDevelopmentExpenditure2017-12-31075335702017-12-3107533570core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:InternallyGeneratedIntangibleAssets2018-01-012018-12-3107533570core:InternallyGeneratedIntangibleAssets2018-01-012018-12-3107533570core:PatentsTrademarksLicencesConcessionsSimilar2018-01-012018-12-3107533570core:DevelopmentCostsCapitalisedDevelopmentExpenditure2018-01-012018-12-3107533570core:OtherPropertyPlantEquipment2017-12-3107533570core:OtherPropertyPlantEquipment2018-01-012018-12-3107533570core:Subsidiary12018-01-012018-12-3107533570core:Subsidiary112018-01-012018-12-3107533570core:Subsidiary122018-01-012018-12-3107533570bus:PrivateLimitedCompanyLtd2018-01-012018-12-3107533570bus:FRS1022018-01-012018-12-3107533570bus:Audited2018-01-012018-12-3107533570bus:SmallCompaniesRegimeForAccounts2018-01-012018-12-3107533570bus:Director12018-01-012018-12-3107533570bus:Director22018-01-012018-12-3107533570bus:Director32018-01-012018-12-3107533570bus:FullAccounts2018-01-012018-12-31xbrli:purexbrli:sharesiso4217:GBP